Publication:
Clinical Outcomes of Extracranial Germ Cell Tumors: A Single Institute's Experience

dc.contributor.authorKamala Laohverapanichen_US
dc.contributor.authorJassada Buaboonnamen_US
dc.contributor.authorNassawee Vathanaen_US
dc.contributor.authorKleebsabai Sanpakiten_US
dc.contributor.authorChayamon Takpraditen_US
dc.contributor.authorNattee Narkbunnumen_US
dc.contributor.authorBunchoo Pongtanakulen_US
dc.contributor.authorPanjarat Sowithayasakulen_US
dc.contributor.authorKamon Phuakpeten_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.date.accessioned2022-08-04T11:05:38Z
dc.date.available2022-08-04T11:05:38Z
dc.date.issued2021-01-01en_US
dc.description.abstractObjective: To determine the clinical features and treatment outcomes of pediatric extracranial germ cell tumor (EGCT) in Thailand. Materials and Methods: A retrospective chart review of children under 15 years old with newly diagnosed EGCT who were treated at Faculty of Medicine Siriraj Hospital from January, 2004 to December, 2013 was conducted. Results: Forty-four patients were included in the study. The median age at diagnosis was 1.74 years (1 day-14.7 years) with the median follow up time of 6.9 years (14 days-15.2 years). Twenty-eight patients (64%) had extragonadal tumor. The most common primary tumor location was the sacrococcygeal area. Majority of the patients (61%) had malignant EGCT; yolk sac tumor was the most common diagnosis. Six patients (14%) had stage IV disease. Forty patients (91%) underwent surgery; 27 patients (61%) received chemotherapy. Thirty-eight patients (86%) achieved remission; 3 patients (7%) subsequently relapsed at a median time of 1 year. Eight patients (18%) died, mostly from tumor progression. The 5-year event-free survival (EFS) and overall survival (OS) rate were 78.3% and 81.1%, respectively. Patients achieving total tumor removal had significantly better 5-year EFS and OS. Cox regression analysis revealed that the adequacy of surgery was the only prognostic factor for survival. Conclusion: The survival rate of pediatric EGCT in our study was relatively favorable, but still inferior to that of developed countries. Novel therapy may be warranted for those patients who are unresponsive to the current treatment.en_US
dc.identifier.citationSiriraj Medical Journal. Vol.73, No.10 (2021), 680-686en_US
dc.identifier.doi10.33192/Smj.2021.87en_US
dc.identifier.issn22288082en_US
dc.identifier.other2-s2.0-85116794460en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/78590
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85116794460&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleClinical Outcomes of Extracranial Germ Cell Tumors: A Single Institute's Experienceen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85116794460&origin=inwarden_US

Files

Collections